Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo Co Ltd to establish subsidiary and to sell subsidiary to Alfresa Pharma


Thursday, 31 Jul 2014 03:30am EDT 

Daiichi Sankyo Co Ltd:To establish new subsidiary in September to succeed Akita plant, which is currently owned by subsidiary DAIICHI SANKYO PROPHARMA.To sell the new subsidiary named TBC to Alfresa Pharma on April 1, 2015.